Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $405.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective lifted by Morgan Stanley from $312.00 to $405.00 in a report released on Friday morning,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on the company. Raymond James Financial started coverage on Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They set an “outperform” rating and a $370.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the stock an “overweight” rating in a report on Wednesday, July 16th. UBS Group boosted their target price on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Jefferies Financial Group boosted their target price on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a “buy” rating in a report on Monday, July 7th. Finally, Wells Fargo & Company boosted their target price on Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the stock an “equal weight” rating in a report on Monday, June 30th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twenty-three have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $392.13.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $401.80 on Friday. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. The stock has a 50 day simple moving average of $318.24 and a 200-day simple moving average of $279.01. The company has a market cap of $52.67 billion, a PE ratio of -162.67 and a beta of 0.25. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $402.43.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 444.38% and a negative net margin of 12.96%. The business had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. The business’s quarterly revenue was up 20.2% on a year-over-year basis. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the business’s stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the sale, the chief executive officer directly owned 48,948 shares of the company’s stock, valued at $14,978,088. The trade was a 28.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Bayforest Capital Ltd grew its holdings in shares of Alnylam Pharmaceuticals by 14.6% during the 1st quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 39 shares in the last quarter. Investment Management Corp of Ontario grew its holdings in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock valued at $1,670,000 after acquiring an additional 40 shares in the last quarter. Brevan Howard Capital Management LP grew its holdings in shares of Alnylam Pharmaceuticals by 3.4% during the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock valued at $314,000 after acquiring an additional 44 shares in the last quarter. Fulton Bank N.A. grew its holdings in shares of Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Fulton Bank N.A. now owns 1,421 shares of the biopharmaceutical company’s stock valued at $463,000 after acquiring an additional 46 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in shares of Alnylam Pharmaceuticals by 10.3% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company’s stock valued at $142,000 after acquiring an additional 49 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.